glp-1 layoffs news Novo Nordisk to cut 9,000 jobs to compete in market The GLP-1 Exit Plan: The

In the STEP UP trial, adults living with obesity who received semaglutide 7.2mg achieved an average weight loss of 18.7% over 72 weeks, compared with 15.6% with 2.4mg and 3.9% with placebo

At the starting dose of 0.25 mg per week, one vial lasts 20 weeks

At least one other instance of ischemic colitis associated with semaglutide use has been described [9], and more may come to light as the population exposed to this drug increases in size

However, it is critical to emphasize that the clinical data included in this meta-analysis do not directly demonstrate activation or inhibition of these pathways at the tissue or molecular level